🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Tab Metformin + Tab Empagliflozin

Found 64 matching trials

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

PHASE1

The aim of the study is to investigate the possible protective effect of em...

Status

Completed

Location

Faculty of pharmacy

Start Date

2022-01-20

Trial ID

NCT05977465

Treatments Being Tested

Empagliflozin 25 MG

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

PHASE1

The trial is being conducted to establish the bioequivalence of emp/met (12...

Status

Completed

Location

1276.24.001 Boehringer Ingelheim Investigational Site

Start Date

2014-01

Trial ID

NCT02028767

Treatments Being Tested

Empagliflozin 2.5 mg Empagliflozin 10 mg Metformin 500 mg Empagliflozin/Metformin FDC

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

PHASE3

The purpose of this research study is to evaluate the efficacy and safety o...

Status

Completed

Location

Phoenix Children's Hospital

Start Date

2018-03-20

Trial ID

NCT03429543

Treatments Being Tested

Metformin Insulin Placebo Linagliptin Empagliflozin

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

PHASE4

The study titled "Efficacy and Safety of Omarigliptin, A Weekly Dipeptidyl ...

Status

Unknown

Location

BIRDEM General Hospital

Start Date

2024-09

Trial ID

NCT06449235

Treatments Being Tested

Omarigliptin Sulphonylureas Metformin Other DPP4-i Thiazolidinediones Alpha-Glucosidase Inhibitor Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA)SGLT2 inhibitors

Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin

PHASE3

The objective of this study is to evaluate the efficacy and safety of tenel...

Status

Completed

Location

Seoul National University Hospital

Start Date

2022-10-12

Trial ID

NCT05504226

Treatments Being Tested

Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet Teneligliptin Placebo Oral Tablet

To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers

PHASE1

This is a randomized, open-label, single dose, crossover, phase 1 trial to ...

Status

Unknown

Location

Multiple Locations

Start Date

2024-07-04

Trial ID

NCT06492655

Treatments Being Tested

CKD-383(Fed)CKD-383(Fasted)

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

PHASE3

This study will investigate the efficacy and safety of BI 10773 in type 2 d...

Status

Completed

Location

1245.19.10056 Boehringer Ingelheim Investigational Site

Start Date

2010-09

Trial ID

NCT01210001

Treatments Being Tested

Placebo BI 10773 Placebo Placebo Placebo BI 10773

Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose

PHASE2

This study will test the effect of four common oral anti-diabetic agents on...

Status

Unknown

Location

Oslo University Hospital, Aker Hospital

Start Date

2021-02-10

Trial ID

NCT04662866

Treatments Being Tested

Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

PHASE1

The aim of the trial is to assess the relative bioavailability of fixed dos...

Status

Completed

Location

1276.23.86002 Boehringer Ingelheim Investigational Site

Start Date

2014-05

Trial ID

NCT02102932

Treatments Being Tested

5 mg empagliflozin/850 mg metformin FDC 12.5 mg empagliflozin 12.5 mg empagliflozin 850 mg metformin 5 mg empagliflozin 5 mg empagliflozin 850 mg metformin 12.5 mg empagliflozin/850 mg metformin FDC 12.5 mg empagliflozin/500 mg metformin FDC 5 mg empagliflozin/500 mg metformin FDC 500 mg metformin 500 mg metformin

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets

PHASE1

An open label, randomized, two-period, two treatment, two-sequence, crossov...

Status

Completed

Location

Cliantha Research Limited

Start Date

2026-03-07

Trial ID

NCT07691203

Treatments Being Tested

Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet Trijardy® XR Tablets

Previous Next